Real-world Experience with Tafamidis in patients with Cardiac Amyloidosis

Introduction: Transthyretin cardiac amyloidosis (ATTR) is an infiltrative cardiomyopathy that frequently presents with heart failure, aortic stenosis, and conduction abnormalities. Tafamidis, a transthyretin stabiliser, has shown efficacy in preventing amyloid formation and is the first specific treatment approved in Spain for this condition. The ATTR-ACT study, published in 2018, demonstrated significant clinical and prognostic benefits with this drug.

Objectives: The aim of this study was to describe the clinical and demographic profile of patients with ATTR treated with tafamidis in our area, to evaluate their clinical and analytic evolution, and to compare these results with those reported in the ATTR-ACT study.